Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Step-Ups in DNA Chip IPOs

This article was originally published in Start Up

Executive Summary

Companies focused on DNA chips have been perennial favorites of the IPO market, from Affymetrix Inc.'s $90 million IPO in April 1996 to Nanogen Inc.'s $64 million offering, Affymetrix, Hyseq Inc., Vysis Inc. and Nanogen Inc. all received pre-money valuations about 3-4 times the total amount paid in by private investors prior to IPO, and post-money multiples of about 4.5 to 5.5.

You may also be interested in...



Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue

While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.

Biopharma VCs Move to the Middle in 2006

While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.

Biopharma IPOs Start Swing Back to Nasdaq

The trend of biopharma IPOs eschewing Nasdaq for European and other exchanges reverses modestly in 2006.

Topics

Related Companies

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel